Aerius

País: Armênia

Língua: inglês

Origem: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Ingredientes ativos:

desloratadine

Disponível em:

Schering-Plough Labo N.V.

DCI (Denominação Comum Internacional):

desloratadine

Dosagem:

5mg

Forma farmacêutica:

tablets film-coated

Tipo de prescrição:

OTC

Características técnicas

Page 1 of 5
Summary of Product Characteristics
Aerius
®
tablets
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Aerius tablets 5 mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 5 mg of desloratadine.
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Coated tablets
4.
CLINICAL PARTICULARS
_4.1 _
_THERAPEUTIC INDICATIONS _
For relief of allergic symptoms such as sneezing, nasal discharge and
itching, as
well as ocular itching, tearing and redness, and itching of palate.
For relief of
symptoms associated with urticaria such as itching and rash.
_4.2 _
_POSOLOGY AND METHOD OF ADMINISTRATION _
For relief of symptoms associated with allergic rhinitis (including
intermittent and
persistent) and urticaria, Aerius
®
is taken with or without meal.
Adults and adolescents (12 years of age and over) take one tablet (5
mg) once a day.
Intermittent allergic rhinitis (presence of symptoms for less than 4
days per week
or for less than 4 weeks) should be managed in accordance with the
evaluation of
patient's disease history. The treatment should be discontinued after
symptoms
are resolved and reinitiated upon their reappearance. In persistent
allergic rhinitis
(presence of symptoms for 4 days or more per week and for more than 4
weeks),
continued treatment may be proposed to the patients during the
allergen exposure
periods.
_Additional information for special populations _
_Geriatric population: _
The safety and efficacy of Aerius
®
has not been established for geriatric population.
_Renal impairment: _
Aerius
®
should be used with caution in patients with severe renal failure.
_Hepatic impairment: _
There is no data regarding administration of Aerius
®
in patients with hepatic
impairment.
_4.3 _
_CONTRAINDICATIONS _
Hypersensitivity to the active substance or to any of the excipients.
_4.4 _
_SPECIAL WARNINGS AND PRECAUTIONS FOR USE _
Efficacy and safety of Aerius
®
tablets in children under 12 years of age have not
been established (a tablet cannot be divided in